Marinos Tsiatas

Queen Mary University of London — United Kingdom

Medicine · Health Sciences

22h-index2.4kcitations65works5.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(13), Immune Cell Function and Interaction(12), Immunotherapy and Immune Responses(10), Bladder and Urothelial Cancer Treatments(9), Prostate Cancer Treatment and Research(9)

Publications63 total

2524eP Real-world treatment patterns, efficacy and survival outcomes in men with mCRPC in Greece: The ProsThera study
Annals of Oncology·2025Open Access
3083P JAVELIN bladder medley phase II trial of avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Subgroup analyses based on metastatic sites
Annals of Oncology·2025
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
The Lancet Oncology·2025· 11 cited
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis
Annals of Oncology·2025· 4 citedOpen Access
Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial.
Journal of Clinical Oncology·2025· 3 cited
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece
Expert Review of Pharmacoeconomics & Outcomes Research·2025· 1 cited
The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study
Clinical Genitourinary Cancer·2024· 1 cited
LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study
Annals of Oncology·2024· 5 citedOpen Access
Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The PROSPECT Study
Clinical Genitourinary Cancer·2024· 1 citedOpen Access
CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2024· 31 cited
Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing
International Journal of Molecular Sciences·2023· 2 citedOpen Access
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens
Urologic Oncology Seminars and Original Investigations·2022· 2 cited
SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non-muscle-invasive bladder cancer unresponsive to bacillus Calmette–Guérin who are ineligible for or decline radical cystectomy
European Urology Open Science·2021· 2 citedOpen Access
SunRISe-2: a phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder
European Urology Open Science·2021· 2 citedOpen Access
Is there a role of repeat cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with relapse from peritoneal metastatic disease? A survival analysis.
PubMed·2021· 2 cited
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group
Cancer Immunology Immunotherapy·2021· 39 citedOpen Access
Upfront or intermediate treatment of advanced ovarian cancer patients with cytoreduction plus HIPEC: Results of a retrospective study
Journal of Surgical Oncology·2020· 8 cited
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology·2020· 487 citedOpen Access
Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC
Pleura and Peritoneum·2020· 8 citedOpen Access
PCN218 COST-EFFECTIVENESS OF APALUTAMIDE + ADT VERSUS ENZALUTAMIDE + ADT IN NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER IN GREECE
Value in Health·2019· 4 cited
page 1 of 4Next →

Frequent Co-authors

Meletios Α. Dimopoulos(17), Aristotelis Bamias(11), Ourania Tsitsilonis(9), Kyriaki Mystakidou(9), Lambros Vlahos(9), George Fountzilas(8), Emmanuela Katsouda(7), Alexandros Rodolakis(6), Aristotle Bamias(5), Dimitrios Pectasides(5), Christos Papadimitriou(5), Flora Zagouri(5), Evangelos Bournakis(5), George Vlahos(4), A. Antsaklis(4), Amanda Psyrri(4), Efi Parpa(4), Margarita Skopeliti(4), Eleni Tsilika(4), Michiel S. van der Heijden(3)